• Glaukos seeks to ‘transform glaucoma therapy'

    One year ago - By Healio

    Four new iStent devices are in the product pipeline, along with an intraocular drug delivery device, according to Thomas W. Burns, president and CEO of Glaukos, at the 36th Annual J.P. Morgan Healthcare Conference.
    Glaukos is using an algorithm to transform glaucoma therapy with products planned to treat the full range of glaucoma, Burns said in the conference webcast.
    “Glaukos now has five distinct products that we are targeting to become commercially available within the next 5 years. For a newly christened IPO company, that is an impressive font for growth. Most newly public medical
    Read more ...